GENFIT Reports Financial Metrics for 2024

GENFIT has disclosed its financial status as of December 31, 2024. The company's cash position was €81.8 million, showing a slight increase from €77.8 million at the same time in 2023. This financial status reflects the impact of significant R&D investments in the ACLF franchise and other medical initiatives.

Revenues for the year reached €67.0 million, significantly higher than €28.6 million in 2023. A crucial milestone payment of €48.7 million from Ipsen, related to the first U.S. sale of Iqirvo®, contributed notably to this growth. The strategic Ipsen partnership continues to play a significant role in GENFIT's financial outcomes.

A royalty financing agreement of €185 million was signed, providing non-dilutive capital to support operations through 2027. This future-oriented financial planning highlights GENFIT's commitment to sustaining its long-term projects and meeting strategic goals.